Ensign Peak Advisors
RCUS icon

Ensign Peak Advisors’s Arcus Biosciences RCUS Stock Holding History

Ensign Peak Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.46M Buy
+252,933
New +$5.46M 0.01% 512
2022
Q4 		– Sell
-9,880
Closed -$258K – 2125
2022
Q3 		$258K Hold
9,880
– – ﹤0.01% 1773
2022
Q2 		$250K Hold
9,880
– – ﹤0.01% 1728
2022
Q1 		$312K Hold
9,880
– – ﹤0.01% 1736
2021
Q4 		$400K Buy
+9,880
New +$383K ﹤0.01% 1704
2021
Q1 		– Sell
-15,972
Closed -$415K – 1875
2020
Q4 		$415K Sell
15,972
-1,774
-10% -$42.9K ﹤0.01% 1635
2020
Q3 		$304K Buy
+17,746
New +$396K ﹤0.01% 1616

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ensign Peak Advisors's RCUS Position: Q1 2026 in Review

Ensign Peak Advisors opened a new position in Arcus Biosciences (RCUS) in Q1 2026: 252,933 shares worth $5.46M. The stake represents 0.01% of the portfolio and ranks #512 among its holdings. This is a return to the name: Ensign Peak Advisors previously reported a position in RCUS as recently as Q3 2022.

Ensign Peak Advisors first reported a position in RCUS in Q3 2020 and has held it in 7 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Ensign Peak Advisors held 252,933 shares of Arcus Biosciences worth $5.46M as of Q1 2026.
  • Arcus Biosciences was a new Ensign Peak Advisors position in Q1 2026.
  • Arcus Biosciences made up 0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #512 holding.
  • Ensign Peak Advisors first reported a position in Arcus Biosciences in Q3 2020 and has held it in 7 quarters since.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.